Medicines for human use under evaluation

Meeting summary - Medicine shortages SPOC working party meeting 15 April 2026

Human medicines European public assessment report (EPAR): Theralugand, lutetium (177Lu) chloride, Date of authorisation: 22/11/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Orkambi, lumacaftor,ivacaftor, Date of authorisation: 19/11/2015, Revision: 39, Status: Authorised

Questions and answers on the refusal of a change to the marketing authorisation for Hetlioz (tasimelteon) (II-40)

Human medicines European public assessment report (EPAR): Pazenir, paclitaxel, Date of authorisation: 06/05/2019, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Zandoriah, teriparatide, Date of authorisation: 27/04/2026, Status: Authorised

Policy 84: Multilingualism on the EMA website and in external communications

EMEA-001134-PIP01-11

PSUSA/00001263/202507